
Hypertension in a randomized trial of DTG- vs EFV-based ART in pregnant and postpartum women

Risa Hoffman, Sean Brummel, Mauricio Pinilla, Grace Malonga, Lameck Chinula, Sherika Hanley, Lynda Stranix-Chibanda, Elizabeth Stankiewicz Machado, Shilpa Naik, Katie McCarthy, Chelsea Krotje, Patrick Jean-Philippe, Paul Sax, Judith Currier, and Shahin Lockman, on behalf of the IMPAACT 2010 Study Team



IMPAACT 2010 (VESTED) Background



Enrolled at 22 sites in 9 countries (Botswana, Brazil, India, South Africa, Tanzania, Thailand, Uganda, US, Zimbabwe) (N=643)

Post-hoc analysis of blood pressure (BP) data over the study period




Lockman et al, Lancet April 2021; Chinula et al, Lancet HIV June 2023

N=21

IMPAACT 2010 Key Relevant Findings

- Significantly lower rate of composite adverse pregnancy outcome (preterm delivery, SGA, or stillbirth) in DTG+FTC/TAF arm compared with other 2 arms¹
- Antepartum weight gain in all 3 arms was lower than recommended by Institute of Medicine² but closest to recommended in DTG+FTC/TAF; highest rate of insufficient weight gain with EFV/FTC/TDF
- Participants in DTG arms more likely to have BMI in overweight/ obese category by 50 weeks postpartum¹



1-Hoffman et al; CID 2024 Jan 5; 2-Institute of Medicine National Academies Press; 2009

Methods: Data Collection and Statistics

- Objective: To characterize elevated BP and hypertension during pregnancy and postpartum
- BP and weight measured at each visit (every 4 weeks antepartum; delivery; 5 times through 50 weeks postpartum), height measured at entry
- Summarized the occurrence of elevated BP and incident mild or worse hypertension through 50 weeks postpartum
- Summarized incident gestational hypertension, preeclampsia, eclampsia (antepartum through 12 weeks postpartum)
- Cox proportional hazard model for by-arm comparisons of occurrence of elevated BP or incident mild or worse hypertension through 50 weeks postpartum
 - Analysis done with and without adjustment for time-varying weight



Methods: Blood Pressure Definitions for Incident Events

Hypertension from antepartum to 50 weeks postpartum: ≥2 values, or initiation of antihypertensive medication*	Category		
Elevated blood pressure**	130-139 and/or 80-89 mmHg		
Mild hypertension	140-159 and/or 90-99 mmHg		
Moderate hypertension	160-179 and/or 100-109 mmHg		
Severe hypertension	≥180 and/or ≥110 mmHg		
Gestational hypertension: onset ≥20 weeks gestation with resolution by 12 weeks postpartum (≥2 values or initiation of antihypertensive medication*)	Category		
Mild gestational hypertension	≥140-159 and/or ≥90-109 mmHg		
Severe gestational hypertension	≥160 and/or ≥110 mmHg		

*First BP value defined the category if second was the same or higher; If second was lower, the lower value defined the category; new antihypertensive medication(s) were not systematically collected

**Defined as stage 1 hypertension by 2017 AHA/ACC Guidelines


Preeclampsia and eclampsia were reported by sites based on local definitions




Maternal Baseline Characteristics

	DTG+FTC/TAF (N = 217)	DTG+FTC/TDF (N = 215)	EFV/FTC/TDF (N = 211)	Total (N = 643)
Age (median years)	26.8	26.0	26.6	26.6
Enrolled in Africa	187 (86%)	189 (88%)	188 (89%)	564 (88%)
Gestational age (median weeks)	22.1	21.3	22.1	21.9
CD4 count (median cells/mm ³)	467	481	439	466
HIV-1 RNA (median copies/mL)	781	715	1357	903
Enrollment weight, mean kg (SD), mean BMI kg/m² (SD)	67.7 (15.1) 26.6 (5.8)	66.3 (16.8) 26.0 (6.2)	64.5 (13.3) 25.2 (4.7)	66.2 (15.2) 25.9 (5.6)
Chronic hypertension or gestational hypertension	6 (2.8%)	7 (3.3%)	4 (1.9%)	17 (2.6%)
Taking antihypertensive medication	4 (1.8%)	5 (2.3%)	2 (0.9%)	11 (1.7%)

Results: Occurrence of elevated blood pressure and incident mild or worse hypertension by arm, antepartum through 50 weeks postpartum




Results: Gestational hypertension (HTN), preeclampsia, and eclampsia



Preeclampsia/eclampsia based on site report of diagnosis and not standardized across the study




Results: Hazard ratios for occurrence of elevated blood pressure and incident hypertension by arm, antepartum through 50 weeks postpartum



ns were similar when adjusted for weight Results similar for antepartum vs postpartum vs overall

Results: Hazard ratios for occurrence of elevated blood pressure and incident hypertension by arm, antepartum through 50 weeks postpartum



Independent of treatment:

- For every 5 kg increase in weight: ≈16-22% increase in the hazard of elevated blood pressure or mild or worse hypertension
- Non-significant trend for increased hazard in by-arm comparisons, more notable for DTG+FTC/TAF vs EFV/FTC/TDF



Unadjusted HR (95% CI)

*HRs for by-arm comparisons were similar when adjusted for weight

Results similar for antepartum vs postpartum vs overall

Conclusions

- High proportion of young women had elevated BP (130-139/80-89 mmHg)
 Clinical significance unclear
- Low incidence of mild or worse hypertension (≥140/90 mmHg)
- Gestational hypertension/preeclampsia/eclampsia uncommon and less common than in cohorts from Africa (women without HIV)¹
- Independent of treatment arm, weight associated with increased hazard of elevated blood pressure and incident hypertension
 - More participants on DTG in overweight/obese BMI categories at 50 weeks postpartum²
- However, important benefits of DTG-based ART in pregnancy/postpartum
 - Healthier antepartum weight gain and lower risk of adverse pregnancy outcomes (especially DTG/TAF)²
- Given benefits of DTG-based ART in pregnancy/postpartum, focus should be on healthy weight and identification and management of hypertension

MPAACT hternational Maternal Pediatric Adolescent AIDS Clinical Trials Network

1-Gemechu et al; Women's Health 2020 (Vol 16); 2-Hoffman et al; CID 2024

Acknowledgements

The IMPAACT 2010/VESTED Protocol Team gratefully acknowledges the dedication and commitment of the 643 mother-infant pairs, their communities, and CAB representatives, without whom this study would not have been possible.

Sponsors:

US National Institutes of Health (Patrick Jean-Philippe,

Renee Browning, Lynette Purdue, Nahida Chakhtoura) Gilead Sciences, Mylan, ViiV Healthcare Ltd

Protocol Co-Chairs: Shahin Lockman and Lameck Chinula

Operations Center: Anne Coletti and Katie McCarthy

Statistical and Data Management Center: Sean Brummel, Lauren Ziemba, Benjamin Johnson, Chelsea Krotje, Kevin Knowles, Kyle Whitson

Laboratory Center: Frances Whalen, William Murtaugh, Sikhulile Moyo

Protocol Team Investigators: Rivet Amico, Judith Currier, Lee
Fairlie, Lisa Frenkel, Risa Hoffman, Lew Holmes, Gaerolwe
Masheto, Mark Mirochnick, Jeremiah Momper, Chelsea Morroni,
Paul Sax, Roger Shapiro, Lynda Stranix-Chibanda, Jeffrey Stringer
Community: Nagawa Jaliaah, Cheryl Blanchette

Site Investigators of Record:

Botswana: Gaborone and Molepolole: Gaerolwe Masheto **Brazil:** Inst de Puericultura e Pediatria Martagao Gesteira: Elizabeth Machado; Hosp Fed dos Servidores do Estado: Esaú João; SOM Fed Univ Minas Gerais: Jorge Pinto; Hosp Geral de Nova Iguacu: Jose Pilotto India: BJMC: Pradeep Sambarey South Africa: CAPRISA-Umlazi: Sherika Hanley; FAMCRU: Gerhard Theron; Soweto: Haseena Cassim; Wits RHI Shandukani: Lee Fairlie Tanzania: KCMC: James Ngocho Thailand: Siriraj: Kulkanya Chokephaibulkit; Chiang Rai: Jullapong Achalapong; Chiang Mai Univ: Linda Aurpibul Uganda: MUJHU: Deo Wabwire; Baylor-Uganda: Violet Korutaro United States: Univ Miami: Gwendolyn Scott; Univ Fl Jacksonville: Mobeen Rathore Zimbabwe: St. Mary's: Patricia Mandima; Seke North: Lynda

Stranix-Chibanda; Harare Family Care: Tichaona Vhembo



Acknowledgements

IMPAACT 2010/VESTED is funded by the US National Institutes of Health (NIH).

Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), and by NICHD contract number HHSN275201800001I.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

The study products were provided by ViiV Healthcare Ltd, Gilead Sciences, Mylan.

